CA3208743A1 - Composition pharmaceutique contenant un anticorps anti-tslp - Google Patents

Composition pharmaceutique contenant un anticorps anti-tslp Download PDF

Info

Publication number
CA3208743A1
CA3208743A1 CA3208743A CA3208743A CA3208743A1 CA 3208743 A1 CA3208743 A1 CA 3208743A1 CA 3208743 A CA3208743 A CA 3208743A CA 3208743 A CA3208743 A CA 3208743A CA 3208743 A1 CA3208743 A1 CA 3208743A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
seq
buffering agent
tslp
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3208743A
Other languages
English (en)
Inventor
Lingjie Kong
Yanju CHENG
Xiaolu Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CA3208743A1 publication Critical patent/CA3208743A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant un anticorps anti-TSLP, et son utilisation. En particulier, l'invention concerne une composition pharmaceutique contenant (a) un anticorps anti-TSLP, (b) un tampon, (c) un tensioactif et un ou plusieurs (d) stabilisants, ainsi qu'une utilisation de la composition pharmaceutique dans la préparation d'un médicament pour le traitement et la prévention de maladies associées à TSLP.
CA3208743A 2021-03-03 2022-03-02 Composition pharmaceutique contenant un anticorps anti-tslp Pending CA3208743A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110235660.8 2021-03-03
CN202110235660 2021-03-03
PCT/CN2022/078718 WO2022184074A1 (fr) 2021-03-03 2022-03-02 Composition pharmaceutique contenant un anticorps anti-tslp

Publications (1)

Publication Number Publication Date
CA3208743A1 true CA3208743A1 (fr) 2022-09-09

Family

ID=83154726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3208743A Pending CA3208743A1 (fr) 2021-03-03 2022-03-02 Composition pharmaceutique contenant un anticorps anti-tslp

Country Status (10)

Country Link
EP (1) EP4302778A1 (fr)
JP (1) JP2024512267A (fr)
KR (1) KR20230152062A (fr)
CN (1) CN116897053A (fr)
AU (1) AU2022229993A1 (fr)
CA (1) CA3208743A1 (fr)
IL (1) IL305230A (fr)
MX (1) MX2023009971A (fr)
TW (1) TW202235437A (fr)
WO (1) WO2022184074A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092064A1 (fr) * 2022-10-26 2024-05-02 Amgen Inc. Compositions d'anticorps anti-tslp et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
BR112018003326A2 (pt) * 2015-09-09 2018-09-18 Novartis Ag anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
KR20180088906A (ko) * 2015-12-18 2018-08-07 아스텔라스세이야쿠 가부시키가이샤 항인간 tslp 수용체 항체 함유 의약 조성물
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN110538321B (zh) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
JP2022535808A (ja) * 2019-06-04 2022-08-10 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CN113423733B (zh) * 2019-09-04 2023-09-22 正大天晴药业集团股份有限公司 结合tslp的抗体及其用途

Also Published As

Publication number Publication date
AU2022229993A9 (en) 2024-02-22
KR20230152062A (ko) 2023-11-02
AU2022229993A1 (en) 2023-10-05
TW202235437A (zh) 2022-09-16
JP2024512267A (ja) 2024-03-19
CN116897053A (zh) 2023-10-17
MX2023009971A (es) 2023-09-05
EP4302778A1 (fr) 2024-01-10
IL305230A (en) 2023-10-01
WO2022184074A1 (fr) 2022-09-09

Similar Documents

Publication Publication Date Title
JP6548696B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
WO2019062832A1 (fr) Anticorps tigit, fragment de liaison à l'antigène de celui-ci, et son utilisation médicale
WO2018089508A2 (fr) Anticorps anti-cd47
JP6250395B2 (ja) α２インテグリンに結合するペプチド又はペプチド複合体並びにそれに関与する方法及び使用
EP3632932A1 (fr) Anticorps anti-cd40, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
US20170152313A1 (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
JP2021503280A (ja) 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
TW202003570A (zh) 抗trem-1抗體及其用途
WO2019184935A1 (fr) Anticorps anti-cd27, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
JP6501650B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
EP4302778A1 (fr) Composition pharmaceutique contenant un anticorps anti-tslp
US20200131263A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2019109974A1 (fr) Anticorps anti-pd-l1 et fragment de liaison à l'antigène de celui-ci
WO2022126416A1 (fr) Anticorps anti-bcma, son procédé de préparation et son application
IL310427A (en) Pharmaceutical preparation of anti-R4IL antibody and use thereof
US20210380696A1 (en) Anti-pd-1 antibodies
US20240067758A1 (en) Multi-specific antibodies and antibody combinations
CA3231553A1 (fr) Composition pharmaceutique comprenant un anticorps bispecifique anti-pvrig/tigit
JP2022540904A (ja) ヒトｔｒｅｍ－１に対する抗体およびその使用
CA3225970A1 (fr) Composition pharmaceutique d'anticorps anti-angptl3 ou de fragment de liaison a l'antigene de celui-ci et son application
NZ788350A (en) Binding molecule specific for LIF and use thereof